Sage Therapeutics: Fooling Some Of The People All Of The Time
Seeking Alpha,
Summary SAGE commands a $3.3B market cap based on its experimental drug SAGE-547.
Extrasynaptic GABAA Receptors
Overview of attention for book
Table of Contents
-
Altmetric BadgeBook Overview
-
Altmetric BadgeChapter 1 Extrasynaptic GABAA Receptors
-
Altmetric BadgeChapter 2 Extrasynaptic GABAA Receptors: Subunit Composition, Distribution, and Regulation
-
Altmetric BadgeChapter 3 Biophysical Properties of Recombinant γ2- and δ-subunit Containing GABAA Receptors
-
Altmetric BadgeChapter 4 The Pharmacology of Extrasynaptic GABAA Receptors
-
Altmetric BadgeChapter 5 Neurosteroids and Extrasynaptic GABAA Receptors
-
Altmetric BadgeChapter 6 Sources of GABA That Activate Extrasynaptic GABAA Receptors
-
Altmetric BadgeChapter 7 GPCR Modulation of Extrasynapitic GABAA Receptors
-
Altmetric BadgeChapter 8 Extrasynaptic GABAA Receptors and Tonic Inhibition in Spinal Cord
-
Altmetric BadgeChapter 9 The Role of Peri-synaptic GABA Receptors After Stroke
-
Altmetric BadgeChapter 10 The Role of Extrasynaptic GABAA Receptors in Focal Epilepsy
-
Altmetric BadgeChapter 11 Gain-of-Function of Thalamic Extrasynaptic GABA-A Receptors in Typical Absence Seizures
-
Altmetric BadgeChapter 12 GABAergic Control of the Hypothalamic–Pituitary–Adrenal (HPA) Axis: Role of Extrasynaptic GABAA Receptors
-
Altmetric BadgeChapter 13 Tonic GABAA-Receptor-Mediated Inhibition in Fragile-X Syndrome: A Cause of Dysfunction or a Pathway for a Cure?